AVITA Medical Welcomes Support for RECELL® in Burns in Australia

• Australia’s Medical Services Advisory Committee (MSAC) recognizes RECELL^® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays
  
  

VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia’s Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) to include the use of autologous skin cell suspension (“ASCS”) prepared with RECELL for the treatment of severe acute burn wounds in adults and children.

“MSAC’s position is a powerful endorsement of RECELL’s clinical impact and the difference it makes in patients’ lives,” said Katie Bush, PhD, Senior Vice President, Scientific & Medical Affairs. “It reflects growing confidence in RECELL as a transformative approach in burn care and represents our shared goals of improving outcomes for patients and supporting clinicians with innovative treatment options.”

MSAC concluded that RECELL is as safe and effective as traditional autologous skin grafting, while providing superior outcomes in donor site sparing and reducing the need for additional grafting procedures. MSAC further acknowledged that RECELL can shorten hospital stays, ease patient pain, and minimize scarring.

Severe burns often require surgery to close the wound, which usually involves taking healthy skin from another part of the body and grafting it onto the burn. This process can be painful, leaves lasting scars at the donor site, and often requires long hospital stays.

RECELL works differently. By taking a very small piece of the patient’s own healthy skin, doctors can prepare a suspension of skin cells that is sprayed onto the wound. This can:

• Reduce the need for large skin grafts, lowering pain and scarring at donor sites
• Shorten hospital stays, helping patients recover faster and return to daily life sooner

The MSAC recommendation supports the use of RECELL for:

• Adult patients with burns covering ≥20% of total body surface area (“TBSA”)
• Pediatric patients with burns covering ≥10% TBSA
• Whole-of-face burn wound closure
  
  

About AVITA Medical, Inc.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL^® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm^®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.

To learn more, visit 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as “can,” could,” “usually,” “will,” “would,” and similar words or expressions, and the use of future dates. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation: failure to obtain and/or maintain regulatory approvals and comply with applicable regulations; market reaction to growth or product initiatives; market penetration of our products; changes in the legal or regulatory environments; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company’s control. Any forward-looking statements made herein are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the “Risk Factors” section of the Company’s latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

Investor & Media Contact:

Ben Atkins

Phone

|

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.